Loading publications…
The last 5 uploaded publications
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma
Richard D. Kim, Debashis Sarker, Tim Meyer, Thomas Yau, Teresa Macarulla, Joong‐Won Park, Su Pin Choo, Antoine Hollebecque, Max W. Sung, Ho-Yeong Lim, Vincenzo Mazzaferro, Joerg Trojan, Andrew X. Zhu, Jung‐Hwan Yoon, Sunil Sharma, Zhong-Zhe Lin, Stephen L. Chan, Sandrine Faivre, Lynn G. Feun, Chia-Jui Yen, Jean‐François Dufour, Daniel H. Palmer, Josep M. Llovet, Melissa Manoogian, Meera Tugnait, Nicolas Stransky, Margit Hagel, Nancy E. Kohl, Christoph Lengauer, Cori Ann Sherwin, Oleg Schmidt‐Kittler, Klaus P. Hoeflich, Hongliang Shi, Beni B. Wolf, Yoon‐Koo Kang (2019). First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. Cancer Discovery, 9(12), pp. 1696-1707, DOI: 10.1158/2159-8290.cd-19-0555.
Article145 days agoSAT-086 Tumour-infiltrating regulatory T cells engage Nrf2 signalling to support their metabolic adaptation in hepatocellular carcinoma
Elena Perpiñán, Nicolas Sompairac, Erik Ramon Gil, R. A de Man, Marianna Maddaloni, Christian Schmidl, Diana Marin-Correa, Elisavet Codela, Candice Lima Santos, Juanjo Lozano, David Camell, A. Hernández, Roser Pinyol, Emmanuelle Landmann, Jorge Ariel Torres, Marwa Elgosbi, Ada Sera Kurt, Vrinda Sharma, Marian V. Fleming, Thomas Dowe, Marwo Habarwaa, Yoh Zen, Rosa Miquel, Debashis Sarker, Albena T. Dinkova‐Kostova, Shahram Kordasti, Timothy Tree, Josep M. Llovet, Ajay M. Shah, Gilbert O. Fruhwirth, Erika L. Pearce, Jack Leslie, Alberto Sánchez‐Fueyo, Niloufar Safinia (2025). SAT-086 Tumour-infiltrating regulatory T cells engage Nrf2 signalling to support their metabolic adaptation in hepatocellular carcinoma. Journal of Hepatology, 82, pp. S453-S454, DOI: 10.1016/s0168-8278(25)01286-3.
Article145 days agoFirst-in-human study of BLU-554, a potent, highly-selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation
R. Kim, Shruti Sharma, Tim Meyer, Debashis Sarker, Teresa Macarulla, Mi‐Kyung Sung, Su Pin Choo, Hengxin Shi, Oleg Schmidt‐Kittler, Corinne Clifford, Beni B. Wolf, Josep M. Llovet (2016). First-in-human study of BLU-554, a potent, highly-selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation. European Journal of Cancer, 69, pp. S41-S41, DOI: 10.1016/s0959-8049(16)32704-6.
Article145 days agoData from First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma
Richard D. Kim, Debashis Sarker, Tim Meyer, Thomas Yau, Teresa Macarulla, Joong‐Won Park, Su Pin Choo, Antoine Hollebecque, Max W. Sung, Ho-Yeong Lim, Vincenzo Mazzaferro, Joerg Trojan, Andrew X. Zhu, Jung‐Hwan Yoon, Sunil Sharma, Zhong‐Zhe Lin, Stephen L. Chan, Sandrine Faivre, Lynn G. Feun, Chia‐Jui Yen, Jean‐François Dufour, Daniel H. Palmer, Josep M. Llovet, Melissa Manoogian, Meera Tugnait, Nicolas Stransky, Margit Hagel, Nancy E. Kohl, Christoph Lengauer, Cori Ann Sherwin, Oleg Schmidt‐Kittler, Klaus P. Hoeflich, Hongliang Shi, Beni B. Wolf, Yoon‐Koo Kang (2023). Data from First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. , DOI: 10.1158/2159-8290.c.6548104.v1.
Preprint145 days agoSupplementary Data from First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma
Richard D. Kim, Debashis Sarker, Tim Meyer, Thomas Yau, Teresa Macarulla, Joong‐Won Park, Su Pin Choo, Antoine Hollebecque, Max W. Sung, Ho-Yeong Lim, Vincenzo Mazzaferro, Joerg Trojan, Andrew X. Zhu, Jung‐Hwan Yoon, Sunil Sharma, Zhong‐Zhe Lin, Stephen L. Chan, Sandrine Faivre, Lynn G. Feun, Chia‐Jui Yen, Jean‐François Dufour, Daniel H. Palmer, Josep M. Llovet, Melissa Manoogian, Meera Tugnait, Nicolas Stransky, Margit Hagel, Nancy E. Kohl, Christoph Lengauer, Cori Ann Sherwin, Oleg Schmidt‐Kittler, Klaus P. Hoeflich, Hongliang Shi, Beni B. Wolf, Yoon‐Koo Kang (2023). Supplementary Data from First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. , DOI: 10.1158/2159-8290.22536304.
Preprint145 days ago